We read with interest the paper by Kostis' reporting the results of a retrospective amlysis nf ir subset of hypertensive participants in the XLVD trials. XIEconclusion chat enalapril treatment was assmia ted with diminished cardiovascular morbidity and mortality in this subset is consistent with the findings in the total population of SULVD participants as well as with findings of several similar reports of studies in hypertension and cardiac disease, using a variety of other angiotensin converting enzyme (ACE) inhibitors. We are gratified that these results add one more piece of evidence in support of the thesis we have proclaimed for the past several years, ie, that in the absence of specific indication for other agents or contraindication against ACE inhibition, ACE inhibitors are probably the drug of first choice in treating hypertension.
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Nevertheless, a few points from that paper need further clarification in order to better substantiate the conclusion:
1. Wpre there differences in the baseline character- Baseline characteristk in the placebo and enalapril groups in the two hypertension subsets are shown in Table I . Among the 26 comparisons made, there was only one statistically significant difference between enalapril and placebo groups: nrj3r myocardiz: infarction among patienk wl;:l systolic blood pressure (SBP) 2140 was significantly more frequent in the enalapril group than in the placebo group (P -.034). Overall the comp'?*abilit;r of the placebo and enalapril groups was very good.
In the retrospective analysis of the Studies of Left Ventricular Dyst'unction (SOLVD) database, the hypertensive population of SOLVD was defined in three alternate ways, using three overlapping subsets (history of hypertension, SBP 2 140 mm Hg, artd diastolic blood pressure [DBPJ rrH3 mm Hg 1. The fact that similar results were observed in analyzing all three subsets strengthens the conclusions of the paper. The degree of overlap is as follows: there were 1508 SOLVD Fatients with elevation of SBP at baseline (761 randomized to placebo and 747 randomized to enalapril) and 985 patients VYth elevated DBP at baselir? (481 randomized to placebo and 504 randomized k enalapril). Of these, 576 patients had elevation of both systolir and diastolic blood pressure (285 randomized to placebo and 291 randomized to enalapril). Analysis of this subset was not done because of its smaller size and the significant overlap (58%) with the subset of elevated diastolic blood pressure.
Enalapril use was associated with a lowering of the systolic and diastolic blood pressure in all patient subsets. The mean blood pressure at baseline and at year one and year two of follow-up in the different hypertensive and normotensive subsets is shown in Table  2 . All differences between enalaprii and placebo were statistically significant with T < .Ol with two exceptions: at year one the difference in DBP in the subgroup with high %I' and high DBP was significant with P = .04, ai\d at year two differences in both DBP and SBP were not statistically significant in this smn!:er subgroup. Overall, the average difference in blood pressure between the placebo and enalapril groups was 6/4 mm Hg.
When the data were analyzed according to the change -3f blood pressure between baseline and the 6 weeks follow-up visit, a beneficial effect or trend of enalapril on morbidity and mortality was observed at
